Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HH100937
- Development stage
- Preclinical
- Lead developer
- Haihe
01
Overview
HH100937: sourced facts only. name: "We discovered a potent SOS1 inhibitor, HH100937 that effectively disrupted the interaction between SOS1 and wild-type KRAS or with G12C, G12D or G12V mutations." [DOI:10.1158/1538-7445.am2024-lb031]; target: "We discovered a potent SOS1 inhibitor, HH100937 that effectively disrupted the interaction between SOS1 and wild-type KRAS or with G12C, G12D or G12V mutations." [DOI:10.1158/1538-7445.am2024-lb031]; developer: "1Haihe Biopharma Co., Ltd., Shanghai, China." [DOI:10.1158/1538-7445.am2024-lb031]; stage: "The combination of HH100937 and AMG510 in xenografts led to tumor regression in all mice, while some tumors did not response well to AMG510 monotherapy." [DOI:10.1158/1538-7445.am2024-lb031]
02
Targets
SOS1 (Son of sevenless homolog 1)
Beyond the preview
Go deeper on HH100937.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HH100937.